Otsuka Precision Health launches first digital therapeutic for depression
August 14, 2024
Intended to supplement medications, the six-week, app-based treatment will cost $50 on a cash-pay basis.
Intended to supplement medications, the six-week, app-based treatment will cost $50 on a cash-pay basis.
Stereotaxis (NYSE:STXS) announced that it obtained CE mark in Europe and submitted an FDA 510(k) application for its next-generation surgical robot.